How to Buy Phathom Pharmaceuticals Stock
Phathom Pharmaceuticals Inc
Phathom Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases.
Phathom Pharmaceuticals stock last closed at $3.90, down 3.23% from the previous day, and has decreased 56.71% in one year. It has overperformed other stocks in the Biotechnology industry by 0.21 percentage points. Phathom Pharmaceuticals stock is currently +2.36% from its 52-week low of $3.81, and -80.21% from its 52-week high of $19.71.
At the moment, there are 69.64M shares of PHAT outstanding. The market capitalization of PHAT is $271.58M. In the last 24 hours, 1.19M PHAT shares were traded.
How to Buy Phathom Pharmaceuticals Stock
Wondering how to invest in Phathom Pharmaceuticals stock? Here's how.
- Figure out where to buy Phathom Pharmaceuticals stock: You need to pick a stock brokerage, but don't worry - we've tested dozens of online brokerages and apps to help you decide where to buy Phathom Pharmaceuticals stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've selected.
- Deposit money your investment account: Select your payment method and add your details.
- Analyze Phathom Pharmaceuticals stock: The Phathom Pharmaceuticals ticker symbol is PHAT. Is Phathom Pharmaceuticals stock a good investment? Should you buy shares of PHAT? How do PHAT's underlying business fundamentals look? Do top analysts think Phathom Pharmaceuticals is a good buy? Why has PHAT's stock price moved recently? (Hint: Our stock market research website can help you decide if PHAT is a good stock to buy).
- Make your PHAT buy order: Decide if you will purchase PHAT shares at the current market price or use a limit order to purchase PHAT shares at a specific price.
- Keep an eye on your PHAT investment: Create a watchlist to important updates regarding your new investment in Phathom Pharmaceuticals stock.
Step 1: Figure out where to buy Phathom Pharmaceuticals stock
You need a brokerage account in order to access the NASDAQ market and buy PHAT stock.
Our recommended brokerage: eToro
In our opinion, eToro is the best stock brokerage. eToro gives you:
- You can invest in stocks with zero commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still buy the stock.
- Access to global markets: From Technology to Healthcare, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top stock exchanges.
- Social investing: eToro offers a community with more than 20 million users globally. Talk to, learn from, and copy the crypto trades of top investors.
- Security: eToro is a regulated and licensed fintech leader.
- Buy other financial assets: Such as ETFs and cryptocurrencies.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen your brokerage, the next step is to fill out some personal details so you can invest in PHAT stock today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to start a new trading account.
- Submit your information by pressing the "Create Account" button. Get started with eToro today
Step 3: Deposit money your investment account
Now that you've finished signing up on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Check out this video walkthrough to see the process of depositing funds into your new investment account.
Step 4: Analyze Phathom Pharmaceuticals stock
Once you have chosen the best place to buy Phathom Pharmaceuticals stock, it's important to analyze their stock prior to buying, so you truly wrap your head around the risk as well as the opportunity.
Phathom Pharmaceuticals Metrics
Phathom Pharmaceuticals Overview
WallStreetZen was built to help part-time investors perform more accurate fundamental analysis quickly.
You can view all of the due diligence checks on PHAT's stock page.
What is the fair value of PHAT stock?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge PHAT's true value.
You can do additional valuation research on PHAT's stock here.
PHAT Financial Health Overview
Positive Health Checks:
- PHAT has cash burn of 266905000. It has sufficient cash and short-term investments to cover this for at least one year.
- There are more short-term assets than short-term liabilities on the PHAT balance sheet.
Negative Health Checks:
- PHAT has $300.13M in cash and short term investments. This is not sufficient to cover its annual cash burn of $266.91M.
- There are more long-term liabilities than short-term assets on the PHAT balance sheet.
- PHAT profit margin has gone up by 289.54 percentage points in the past year, but the company is still unprofitable.
- PHAT debt to equity ratio of -2.49 is negative.
- Total PHAT debt is still negative.
Is it a good time to buy PHAT stock, according to Wall Street analysts?
Out of 3 sell side analysts who give ratings on PHAT, the consensus analyst rating on PHAT is a Buy
Please keep in mind that analyst ratings are not recommendations, nor are they investment advice.
You can dive deeper into what analysts are forecasting on the Phathom Pharmaceuticals stock forecast page.
PHAT Trading Indicators
PHAT Performance Metrics
Last year, PHAT revenue was $55.25M. Over the last 1 years, PHAT's revenue has gone up by 8,001.47% per year. This was faster than the Biotechnology industry average of 44.31%.
You can research PHAT's earnings and revenue performance here.
Are PHAT insiders buying or selling the stock?
Over the past year, insiders at PHAT have sold more shares than they have bought.
Molly Henderson, CFO and CBO of PHAT, was the latest PHAT insider to sell. They sold $16,738.58 worth of PHAT stock on Apr 7, 2025.
Get more info about who owns PHAT shares here.
Can I rely on PHAT as an income stream?
No, Phathom Pharmaceuticals doesn't provide an income stream by paying out dividends.
What do other investors have to say about PHAT?
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other community members have to say.
Step 5: Make your PHAT buy order
You have two primary types of orders:
- Market order: A market order is an order to buy or sell a stock at the best price on the market.
Market orders are generally fine for most investors. - Limit order: A limit order lets you buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a specific dollar amount limit, use a limit order.
Press the Open Trade button and eToro will execute the order.
If you want additional help with investing in stocks on eToro, watch the how to video below:
Step 6: Keep an eye on your PHAT investment
Now that you own some shares in PHAT, you'll want to keep up with your new stock purchase.
Add PHAT to a watchlist to keep track of your PHAT stock.
PHAT Feed
How to Buy Stock in Phathom Pharmaceuticals
To summarize, here are the 6 steps for buying Phathom Pharmaceuticals stock:
- Figure out where to buy Phathom Pharmaceuticals stock
- Sign up for your brokerage account
- Deposit money your investment account
- Analyze Phathom Pharmaceuticals stock
- Make your PHAT buy order
- Keep an eye on your PHAT investment
If you are looking for a brokerage account, eToro is our favorite option.
Get Started with eToro TodayIf you would like to get notifications regarding your investment in Phathom Pharmaceuticals, create a watchlist today.
Other Content You May Enjoy
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.